Description

Humacyte, Inc. is a company dedicated to the creation and production of bioengineered human tissues that are readily available and suitable for implantation. These advanced tissues are intended for the treatment of a variety of diseases and medical conditions, applicable to numerous anatomical sites and therapeutic areas. The company employs its distinct, proprietary scientific platform to engineer and manufacture human acellular vessels (HAVs). A significant advantage of these HAVs is their capacity to be implanted into patients without triggering an adverse immune response or leading to rejection by the body. Humacyte is actively developing a diverse portfolio of HAVs, aiming to address needs within the vascular repair, reconstruction, and replacement market. This encompasses uses in cases of vascular trauma, establishing arteriovenous access for hemodialysis, treating peripheral arterial disease, performing pediatric heart surgery, and executing coronary artery bypass grafting. Additionally, their technology supports the delivery of cellular therapies, such as pancreatic islet cell transplantation for managing Type 1 diabetes. Established in 2004, Humacyte, Inc. is headquartered in Durham, North Carolina.